Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Latest Information Update: 11 Jan 2024
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Adverse reactions
- 29 Apr 2021 Planned End Date changed from 1 Jun 2025 to 1 Jun 2026.
- 23 Apr 2021 Status changed from not yet recruiting to recruiting.
- 24 Mar 2021 Planned End Date changed from 1 Apr 2025 to 1 Jun 2025.